Floatz logo

RANITIDINE

Precursor T-Cell Acute Lymphoblastic Leukemia

SanofiSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Precursor T-Cell Acute Lymphoblastic Leukemia cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Sanofi
Phase 2B
Venetoclax
First Affiliated Hospital of Zhejiang University
Phase 2CCC
Benadryl
Sanofi
Phase 2CCC
Omacetaxine
First Affiliated Hospital of Zhejiang University
Phase 2CCC
Cytosin-Arabinosid
First Affiliated Hospital of Zhejiang University
Phase 2CCC

View all 19 →

Same molecule, other indications

RANITIDINE is also rated in:

breast cancerDormant
BB
Indicative ·
64 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
B
Indicative ·
63 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
62 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →